Woodline Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Woodline Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.74M	Hold	171,805	–	–	0.02%	659
2026 Q1	$3.6M	Hold	171,805	–	–	0.01%	722
2025 Q4	$3.95M	Sell	171,805 -101,446	-37%	-$3.34M	0.02%	674
2025 Q3	$8.22M	Hold	273,251	–	–	0.04%	470
2025 Q2	$9.94M	Buy	273,251 +4,789	+2%	+$173K	0.05%	437
2025 Q1	$9.72M	Sell	268,462 -1,094	-0.4%	-$45.5K	0.06%	367
2024 Q4	$11.3M	Buy	269,556 +2,001	+0.7%	+$99.3K	0.08%	313
2024 Q3	$14.9M	Buy	267,555 +765	+0.3%	+$39K	0.13%	229
2024 Q2	$11M	Sell	266,790 -133,334	-33%	-$5.69M	0.1%	238
2024 Q1	$18.7M	Hold	400,124	–	–	0.17%	181
2023 Q4	$19.1M	Buy	400,124 +194,641	+95%	+$7.55M	0.21%	146
2023 Q3	$7.33M	Sell	205,483 -31,081	-13%	-$1.23M	0.09%	256
2023 Q2	$10.9M	Buy	+236,564	New	+$11M	0.13%	196

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Woodline Partners's RARE Position: Q2 2026 in Review

Woodline Partners held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 171,805 shares worth $5.74M. The position accounts for 0.02% of the portfolio, ranked #659.

Woodline Partners first reported a position in RARE in Q2 2023 and has held it in 13 quarters since. The position peaked at $19.1M in Q4 2023. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Woodline Partners held 171,805 shares of Ultragenyx Pharmaceutical worth $5.74M as of Q2 2026.
Woodline Partners left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
Ultragenyx Pharmaceutical made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #659 holding.
Woodline Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
Woodline Partners's Ultragenyx Pharmaceutical position peaked at $19.1M in Q4 2023.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.